Spontaneous, non-sponsored, interventional, controlled, randomized, parallel-arm clinical study. Primary objective To assess the impact of specific dietary approaches (ketogenic diet, Mediterranean diet, or Mediterranean diet supplemented with GABA-producing probiotics, e.g., Bifidobacterium adolescentis PRL2019) on fibromyalgia (FM) severity-particularly pain, sleep quality, anxiety, and depression-using validated questionnaires in female patients with FM and overweight/class I obesity. Secondary objectives * Evaluate effects on anthropometric measures, metabolic profile, and body composition. * Assess changes in gut microbiota composition and metabolomic analysis. * Measure neurosteroids with positive allosteric activity on GABA-A or NMDA receptors in saliva and/or plasma. * Exploratory pilot sub-study to quantify brain GABA and glutamate levels through magnetic resonance spectroscopy (MRS) in a subset of patients. Methods Participants will be recruited from the Rheumatology Unit outpatient clinics of IRCCS Policlinico San Martino Hospital (Genoa). Eligible subjects will be adult women with FM and overweight/obesity, selected through protocol-defined criteria. Enrollment requires written informed consent. At enrollment (baseline), participants will complete validated questionnaires assessing FM severity (pain, sleep quality, depression, anxiety, bowel function). Data collection will include sociodemographic information, Mediterranean diet adherence through PREDIMED questionnaire, basal metabolic rate, medical and dietary history, smoking status, blood pressure, and recent laboratory results. Stool, blood, and saliva samples will be collected for routine tests, metabolomics, and ELISA-based measurement of neuroactive steroids like cortisol, progesterone, DHEA. Within 7 days T1, results will be reviewed and eligible participants randomized to one of three groups: hypocaloric ketogenic diet, Mediterranean diet, or Mediterranean diet plus probiotics. Individualized dietary plans will be provided with written and verbal instructions. Anthropometric measurements (weight, height, BMI, waist circumference, waist-hip ratio) and body composition via bioelectrical impedance analysis BIA will be recorded at T0, T4, T8, and T12, together with biological sample collection. Pilot MRS sub-study A subset of participants will undergo brain GABA and glutamate assessment through MRI spectroscopy performed on a 3T Siemens - Prisma magnet at the baseline, before dietary treatment and after 4 weeks. Results will be compared with spectra from control subjects screened through medical history to exclude relevant diseases.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Assessing the impact of dietary approach on the severity of fibromyalgia, particularly on pain through the Widespread Pain Index (WPI)
Timeframe: Baseline, Week 4, Week 8, and at the end of treatment (up to 12 weeks).
Assessing the impact of dietary approach on the severity of fibromyalgia, particularly on pain through the Symptom Severity Scale (SSS).
Timeframe: Baseline, Week 4, Week 8, and at the end of treatment (up to 12 weeks).
Assessing the impact of dietary approach on the severity of fibromyalgia, particularly on pain through the Fibromyalgia Impact Questionnaire (FIQR).
Timeframe: Baseline, Week 4, Week 8, and at the end of treatment (up to 12 weeks).
Assessing the impact of dietary approach on the severity of fibromyalgia, particularly on pain through the PainDETECT (PD-Q).
Timeframe: Baseline, Week 4, Week 8, and at the end of treatment (up to 12 weeks).
Assessing the impact of dietary approach on the severity of fibromyalgia, particularly on anxiety and depression through The Hospital Anxiety and Depression Scale (HADS).
Timeframe: Baseline, Week 4, Week 8, and at the end of treatment (up to 12 weeks).
Assessing the impact of dietary approach on the severity of fibromyalgia, particularly on sleep quality through the Pittsburgh Sleep Quality Index (PSQI).
Timeframe: Baseline, Week 4, Week 8, and at the end of treatment (up to 12 weeks).
Assess the presence of functional gastrointestinal disorders, in particular Irritable Bowel Syndrome (IBS) through the Rome IV criteria and the Bristol Stool Scale.
Timeframe: Baseline, Week 4, Week 8, and at the end of treatment (up to 12 weeks).